Rgenta Therapeutics Unveils Promising Data on RGT-61159 Inhibitor at EHA 2025 Congress#USA#Rgenta_Therapeutics#Woburn#RGT-61159#MYB_RNA
Rgenta Therapeutics Unveils Promising Data on RGT-61159 Inhibitor at EHA 2025 Congress
Rgenta Therapeutics will present preclinical findings on its innovative MYB RNA inhibitor, RGT-61159, at EHA 2025 in Milan, showcasing significant anti-tumor activity.
third-news.com
May 14, 2025 at 2:34 PM
Rgenta Therapeutics Unveils Promising Data on RGT-61159 Inhibitor at EHA 2025 Congress#USA#Rgenta_Therapeutics#Woburn#RGT-61159#MYB_RNA